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The recent popularity of methods for solid-phase peptide synthesis that use 
the 9-fluorenylmethyloxycarbonyl (Fmoc) group for N-amino protection has created a 
need for compatible anchoring linkages and handles. In an effort to develop mild new 
methods for use in solid-phase peptide synthesis (SPPS), a new ferrocene containing 
linker or “handle”, the 1’1-ferrocenyl carboxaldehyde handle was designed, synthesized, 
characterized and tested. This linker is analogous to those commercially available and 
developed by Barany. The ferrocenyl amine linker(FAL) releases C-terminal peptide 
amides upon acidolysis. Since the FAL handle is acid labile it is compatible with Fmoc 
and N-dithiasuccinoyl (Dts) based chemistries, but not  N-tert-butyloxycarbonyl (Boc) 
based chemistries. The solid-phase linkage was investigated based on the stability of the 
ferrocenium ion. The stability of this ion is greater than that of the benzyl cations that are 
used in the handles developed previously.  
 
CHAPTER ONE 




Since the pioneering work of Merrifield in solid phase peptide synthesis1 in the 1960s, 
several different methods for cleaving peptides have been developed. The cleavage of the 
peptide from the resin is one of the key steps in solid phase peptide synthesis. One 
method which imparts flexibility to the cleavage process is to attach a molecule (linker or 













Solid phase chemistry is currently not as developed as solution-phase chemistry, 
particularly with regard to small organic molecules, but it has some advantages over the 
solution-phase. First, in solid-phase synthesis, large excesses of reagents can be used to 
drive reactions to completion; these excess reagents can then be removed at the end of 
these reactions by filtration and washing. Second, because of easy separation of reagents 
and products, solid-phase chemistry can be automated more easily than solution 
                                                                                                                              1
chemistry. Separation of compounds bound to the solid support from those in solution is 










Figure 1.2 Purification of compounds bound to the solid support from those in solution 
by simple filtration. 
 
 
The solid support describes the insoluble material that is reversibly bound to the 
starting reactants.  Solid-phase reactions can occur on the surface of the solid particles or 
inside these particles. There are several types of materials used as solid supports that 
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allow reactions only on the surface, for example, beads made from glass and cellulose 
fibers2, the reduced surface area in these surface-type solid supports reduces the number 
of functionalization sites. 
Several supports have been developed since the initial introduction of polystyrene 
cross-linked with 2% divinylbenzene (DVB) by Merrifield. The supports can be chosen 
depending on the type of reactions and products desired. Different supports may be 
chosen for different types of chemistries. For example, some supports, such as 
polyethylene glycol (PEG) grafted resins are suitable for use in polar solvents  others 
such as polystyrene are used with nonpolar solvents. The solid support must have the 
following characteristics3 for an efficient solid-phase synthesis:  1) physical stability and 
of the right dimensions to allow for liquid handling and filtration;  2) chemical inertness 
to all reagents involved in the synthesis;  3) an ability to swell while under reaction 
conditions to allow permeation of solvents and reagents to the reactive sites within the 
resin;  4) derivatization with functional groups to allow for the covalent attachment of an 
appropriate linker or first monomeric unit.  In most cases, the linker unit must be 
cleavable under conditions that allow the isolation of the desired product after synthesis 
is complete.    
Cleavage conditions are dictated by the linker used. The key to successful solid 
phase synthesis lies in the protection scheme that is used to assure reaction only at the 
desired position(s).  Most monomeric units (X) used in solid-phase synthesis can be 
expressed with the empirical formula n-X-e, where n is the nucleophilic portion of the 
residue and e is the electrophilic portion.  The first monomeric unit is coupled to the resin 
at either the nucleophilic or the electrophilic site.  However, the portion of the molecule 
that is not covalently bound to the resin must be protected to avoid subsequent 
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polymerization of excess monomers in solution.  Thus, if the electrophilic portion of the 
first residue is coupled to the resin, the nucleophilic portion must be protected, and vice 
versa (figure 1.3).  The protecting group must be stable to the reaction conditions of each 
coupling. After coupling is performed, the protecting group is removed to expose a new 

































=   Solid Support
=  Amino Acid
= Side-chain Protection
   (Semi-Permanent)
=  N-terminal Protection
  (Temporary)
Figure 1.3 General scheme for solid-phase peptide synthesis. 
4
 
If several nucleophilic and/or electrophilic groups are present in a monomeric 
unit, they must be orthogonally protected with groups that vary in reactivity. This allows 
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for deprotection of the portion of the molecule where further reaction is desired to take 
place in subsequent couplings, while preventing reaction at side-chain functional groups.  
SPPS is almost exclusively performed in the C→N direction, with the amino group being 
the nucleophilic portion and the C-terminus the electrophilic portion.  Common 
protecting groups and the conditions under which they are cleaved are listed in Table 1.1   
 
Table 1.1 Common protecting groups used in SPPS where side chains are cleaved under 
mild to moderate acidic conditions. 
 

























































































Acidolysis remains the most popular amongst the synthetic strategies formulated 
towards the cleavage of a peptide from its protecting groups and resin support. The 
acidolytic deprotection reaction is a major component in the overall scheme in two 
widely used stepwise SPPS approaches. The first scheme, the Boc-Bzl strategy adheres to 
the principle of differential acid lability. The second approach, the Fmoc-tBu strategy, is 
becoming more widely used because of the huge reactivity difference between acid-labile 
side-chain protecting groups and the base-mediated cleavage of the Fmoc group. 
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1.2 Literature Review 
This review focuses on linkers designed to be highly acid labile. These linkers are 
predominantly based on the benzylic C-N bond cleavage. Recent advances in linkers 
have allowed other polar functional groups, such as alcohols and thiols, to be attached to 
the polymer support. Polar functionalities such as carboxylic acids and amides are 
released upon cleavage of products from the resin in SPPS. In fact, most of the linkers 
available for solid support synthesis to date require polar functional groups for binding. 
Examples of peptide-resin cleavage are given below for  acid labile linkers;  
The PAL(peptide amide linker)13 handle (figure 1.4) is suitable for cleavage of 
complex peptide amides that contain several sensitive side-chain functionalities or 
arginine residues that contain the blocking groups Mtr or Pmc. The peptide pGlu-Gly-













Resin  =  aminomethyl polystyrene- 2% divinylbenzene 
Peptide= Human Gastrin – I  (pGlu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-
Gly-Trp-Met-Asp-Phe-NH2) 
Yield = 68% (cleavage yield), 37% after HPLC 
Purity = 85% 
Coupling Method=  Fmoc/HOBt/DIPCDI  
Type of Peptide = Peptide amides 
Figure 1.4 Cleavage of peptide from the linker PAL. 
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Substituted benzyl amide14 linkers have been compared. The results showed that 
by adding methoxy groups (figure 1.5) to the benzene and increasing the length of the 
spacer that separates the electron-donating oxygen para to the anchored amino acid from 
the electron-withdrawing alkylamide function linking the handle to the support increased 
the acid liability of the linker. A model peptide (H-Tyr-Gly-Gly-Phe-Met-NH2) was 
prepared and the cleavage yield was about 80% with 90% purity. This linker is suitable to 











Resin  =  Aminomethylcopoly(styrene-1%-divinylbenzene) 
Peptide= analogue methionine-enkephalinamide (H-Tyr-Gly-Gly-Phe-Met-NH2) 
Purity = 90% 
Yield = 80% 
Type of Peptide =  amide 
Coupling Method= Fmoc/DCC/HOBt/DMF 
 
Figure 1.5 Cleavage of peptide from BAL(Backbone amide linker).  
 
 
The trityl linker15 is widely used to prepare small-protected peptides. It can be 
used to obtain thiols, alcohols and amines via cleavage. In this example (figure 1.6) The 
trityl linker was used to synthesize the following peptide: DNP-Pro-Gln-Gly-Ile-Ala-Gly-
Lys(Cum)-Arg-Dah-Acr. 
 












Type of Peptide = peptide hydrazides 
Coupling method= Fmoc/DIPCDI/HOBt 




The Rink linker16 does not allow the use of HOBt as a coupling catalyst without 
buffering with DIPEA. A protected peptide[Fmoc-Asp(Obut)-Arg(Mtr)-Gly-Phe-
Tyr(but)-Phe-Ser(but)-Arg(Mtr)-Pro-Ala-Ser(but)-Arg(Mtr)-Val-Ser(But)-
Arg(Mtr)Arg(Mtr)-Ser(But)-Arg(Mtr)-Gly] was prepared and obtained in 23% yield after 
HPLC (figure 1.7). N-Substituted hydroxamic peptide acids were synthetized using this 
linker in yields of 80-90%. This peptides are isolated from microorganisms are known to 
be potent and selective inhibitors of many metallo proteases 17. A modified Fmoc 
strategy was used to synthesize this peptide using this linker. A 9-residue peptide 
consisting of arginine and tryptophan was prepared with high purity and yield. 










Resin  = polystyrene 
Peptide = Fmoc-Asp(Obut)-Arg(Mtr)-Gly-Phe-Tyr(but)-Phe-Ser(but)-Arg(Mtr)-Pro-Ala-
Ser(but)-Arg(Mtr)-Val-Ser(But)-Arg(Mtr)Arg(Mtr)-Ser(But)-Arg(Mtr)-Gly 
Yield=23 % (after HPLC) 
Type of Peptide = Peptide esters 
Coupling method = Fmoc 
Figure 1.7 Cleavage of peptide from the Rink linker. 
 
 
Benzyl amine linkers in figure 1.8 were compared by Bertnatowicz18. This study 
found that linkers c) and d) (figure 1.8) are the most satisfactory for peptide synthesis. 
These linkers are well suited for peptide C-terminal amides and are compatible with 
Fmoc chemistry. Cleavage is performed with TFA:phenol(95:5) for 2h at room 
temperature. Yields of crude peptides (Eledoisin and Neuromedin) were isolated in  87-
91 % yield for both linkers. 
Benzyloxy dimethoxytrityl amine (BDMTA) resin19 is similar to the trityl resin 
mentioned earlier but in this case two benzene rings have methoxy groups para to the 
benzylic carbon attached to the three phenyl groups (figure 1.9). This linker was used to 
prepare Phe-Thr-Pro-Arg-Leu-NH2 which can be cleaved with dilute TFA. Purity of 
90+% (HPLC) and satisfactory yields 80+% based on resin loading were reported. 


































Peptide= Phe-Thr-Pro-Arg-Leu-NH2  
Yield = 80%+ 
Purity = 90+% 
Coupling Method=  Fmoc/DCC 
Type of Peptide = Peptide Amide 
Figure 1.9 Peptide cleavage from BDMTA resin. 
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Benzhydrylamine(BHA) Resin20 is useful to prepare peptide amides. In this 











Resin  = BHA resin 
Peptide= arginine vasopressin analogue 
Yield = 6% 
Coupling Method=  Fmoc/DCC/HOBt 
Type of Peptide =   Peptide Amide 
Figure 1.10 Cleavage of peptide from BHA resin. 
 
4-Methylbenzhydrylamine (MBHA) linker21  is commonly used in the solid 
phase synthesis of carboxamides, aldehydes and sulfonamides.  This linker is more acid 
labile than the BHA linker due to the effect of the extra methyl group stabilizing the 
cation formed upon cleavage.  TFMSA and HBr/thioanisole in TFA, HF/anisole can also 
cleave the MBHA linker22, 23, 24.   MBHA resin is the standard resin for the synthesis 
of peptide carboxamides by the Boc solid phase synthesis methodology 25. The 
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peptide(figure 1.11) was synthesized using amino acid aldehydes and HOBT/Boc 









Resin  =  MBHA polystyrene 
Peptide=+H3NLeu[CH2N9CH2CH2CH2SH]Ser-Pro-Gly-Lys-
Val[CH2N9CH2CH2CH2SH)]Ala-Pro-Lys-Tyr-NH2 
Purity = low levels of side products 
Yield = 21% (after off-resin disulfide bond cyclization) 
Type of Peptide = amide 
Coupling Method= HOBt/Boc/amino acid aldehydes 
Figure 1.11 Cleavage of peptide from MBHA resin. 
 
Alkoxybenzylamine linker 26 anchors the C-terminal amino acid to the resin by 
the -nitrogen atom(figure 1.12). This linker is similar to BAL but requires harsher 
cleavage conditions. This linker is compatible with the alloc-protect/palladium-deprotect 
chemistry. The linker is also compatible with Boc chemistry and it cleaves from the solid 
support using standard HF cleavage.  The synthesis of stylostatin(a cyclic peptide) with 
on resin cyclization followed by cleavage and HPLC purification gave yields of 10 % for 
the monomer, 25.5 % for the dimmer and 1 % for the trimer. Bourne – Smythe also 
cleaved the peptide, followed by cyclization in solution and the yields, which were 
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dependent on the concentration of DMF, increased for the monomer, were about the same 













Resin  =  Aminomethylpolystyrene Resin 
Peptide = H-Pro-Phe-Asn-Ser-Leu-Ala-Ile-OH 
Resin = Benzyl amine resin 
Yield= 39%(Yields for cyclic peptides range from 10-25%) 
Type of Peptide = Cyclic amide bond 
Coupling Method = HBTU/ DIEA/ DMF 





dihydrodibenzo[a,d]cyclohepten-2-yl]oxy}valeric acid (CHA) and 5-{[R,S)-5-[(9-
fluorenylmethoxycarbonyl)amino]dibenzo[a,d]cyclohepten-2-yl]oxy} valeric acid (CHE)  
linkers (figure 1.13) developed by Noda 27  are suitable for peptide amide preparation 
under mild conditions. The linkers are compatible with Fmoc chemistry. Human Secretin, 
a 27-residue peptide, was prepared on both linkers and cleaved with TFA-H2O-
thioanisole-EMS-EDT-thiophenol (82.5:5:5:3:2.5:2, v/v) at rt for 6 h (Yield 54% for both 
resins). Although this peptide synthesis gave similar yields, the authors found that CHA 
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was a superior handle for the preparation of peptides, especially peptides that contain acid 














Resin  = Tanta Gel S NH2 
Peptide= Human Secretin 
Yield = 54%(after HPLC) 
Purity = 85% 
Coupling Method= HBTU/HOBt/DIEA 
Type of Peptide = Peptide amide 
 
Figure 1.13 Peptide cleavage from CHA and CHE linkers. 
 
 
The semicarbazide linker 28 (figure 1.14) is useful for the synthesis of peptide 
aldehydes and C-terminal semicarbazones. The method proceeds with no loss of 
stereochemical integrity. The peptides can be cleaved from the resin using TFA/H2O(9:1) 
for 1.5 hrs. 















Yield = 50% yield 
Coupling Method= Fmoc amino acids 
Type of Peptide = Peptide Aldehyde 
 
 
Figure 1.14 Peptide cleavage using the semicarbazide linker. 
 
 
 4,4'-dimethoxybenzhydryl derived linkers29 (figure 1.15) are derived from the 
4,4’-dimethoxybenzhydryl (Mbh) group used for the protection of amides. The peptide 
LHRH (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) was synthesized in 43% yield 
after chromatography using linker d in figure 1.15. 
[(5-Carboxylatoethyl-2.4-dimethoxyphenyl)-4’-methoxyphenyl]methylamine 29 
linker in figure 1.16  is another derivative of 4,4’-dimethoxybenzhydryl(Mbh)-protecting 
group for amides. Peptide pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-amide was 
synthesized and cleaved with 95 %TFA, 5 % thioanisole and 5 % ethanedithiol by 
volume (98 % Yield). 
 













a). R,R1,R2 = H 
b). R, R2= H R1= CH3 
c). R = H, R1,R2 = CH3 
d). R = CH2C6H5, R1,R2 = H 
e). R = (CH3)2CH, R1 = CH3, R2 = H 
Peptide = LHRH (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) 
Yield = 43% 
Coupling Method= Fmoc/DCC/HOBt 
Type of Peptide = Peptide Amide 
 








95 %TFA, 5 % thioanisole,




Resin  = aminomethylated polystyrene resin 
Peptide= pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-amide  
Purity = high 
Yield = 98% 
Type of Peptide = amide 
Coupling Method= Fmoc/HOBt/DIC 
 
Figure 1.16 Peptide cleavage using a dimethoxy diphenyl linker.  
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4-Hydroxymethyl-3-methoxyphenoxybutyric acid  (HMPB) 30 is useful to make 
peptide amides. In this work, a dendrimer was attached to the resin to increase the 
loading level of the resin. Here the linker is attached after the dendrimer. The results 
showed that there was only a small increase in substitution. A model peptide consisting 












Resin  = Tenta Gel 
Peptide= 13 residue peptide 
Yield = 44 % (after HPLC) 
Type of Peptide = amide 
 
 




 The 2-chlorotrityl linker 31 is compatible with Fmoc chemistry. This linker is 
useful when using nucleophilic amino acids such as Trp and Met. The purity when using 
Fmoc/Trt amino acids is much higher than when using Fmoc/tBu amino acids. 
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Ser-Peptide
Cl
1.1 % TFA/DCM Peptide
 
Peptide= H-Thr-Thr-Trp-Thr-Ser-Met-Ser-Trp-Tyr-OH 
Purity = 92 % 
Coupling Method=  Fmoc/DCC/HOBt 
Type of Peptide = Peptide carboxylic acid 
Figure 1.18 Peptide cleavage using the 2-chlorotrityl linker. 
 The 2-methoxy-4-benzyloxy-polystyrene aldehyde linker (MALDRE) (figure 
1.19) 32 This linker is useful for the synthesis of C-terminal peptide amides. The peptide 
is cleaved from the resin by treatment with 10-50% trifluoroacetic acid in methylene 
dichloride for 30 minutes. This linker is compatible with the Fmoc/Boc chemistry. The 
resin 2-methoxy-4-benzyloxy polystyrene aldehyde linker MALDRE can be prepared 





R1 = C6H5(CH2)4NH2  
 
Resin  = polystyrene 
Peptide= Tyr-Gly-Gly-Phe-Leu-NHCH2CH2CH2CH2C6H5 
Yield = 44 % after HPLC 
Type of Peptide = amide 
Coupling Method= Fmoc/DIC/HOBt 
Type of Peptide = sec-peptide amides 
Figure 1.19 Peptide cleavage from MALDRE linker. 
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Benzylamine derivatives in figure 1.20 33 were used to prepare the peptide 
thymulin (FTS, pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) was synthesized using both 
handles. The thymulin-resin-NH-resin were treated with 95 % TFA/thioanisole and the 










a). p-NH2-resin: R5 =CH2NH2, R6 = H






Resin  =  Chloromethylcopoly(styrene-1 %-divinylbenzene) 
Peptide= thymulin (FTS, pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) 
Purity =  high 
Yield = 50-95 % 
Type of Peptide = amide 
Coupling Method= Fmoc/DCC/HOBt/ 
 
 
Figure 1.20 Peptide cleavage from methoxy benzyl amine linker. 
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The benzhydrylamine-derived linker is compatible34  with Fmoc chemistry. 






OMe 1 M thioanisole /TFA
 (28 C; 60 min).
Peptide
 
Resin  =  (aminomethyl)polystyrene resin 
Peptide= tetragastrin 
Yield = 41 % yield (cleavage yield 60 %, based on Ile in the resin) 
Coupling Method=  Fmoc/DCC/HOBt 
Type of Peptide = Peptide Amides 
Figure 1.21 Modified Benzhydrylamine linker. 
 
 
4-Benzyloxytritylamine linker35 derivatives were substituted with methoxy 
groups to compare the cleavage of peptides by TFA (figure 1.22). The results showed that 
the methoxy substituents reduce the cleavage time of the peptide amides from 2h for 
BTA to 10 min for 4-benzyloxy-2’,2”,4’,4”-tetramethoxytritylamine (BTEMTA) with 1 
% TFA/DCM. This method allows the preparation of protected peptide amides in high 
yields and purity.  Methoxy groups were also introduced to 9-xanthenylamine linker 
(XAL). The XAL derivatives, 9-amino-9-(4-methoxyphenyl)-xanthene-3-
yloxymethyl(MPXAL) and 9-amino-9-(2,4-dimethoxyphenyl)-xanthene-3-
yloxymethyl(DMPXAL), the peptide oxytocin  (Fmoc-Cys(Trt)-Tyr(tBu)-Ile-Gln(Trt)-
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Asn(Trt)-Cys(Trt)-Pro-Leu-Gly-OH) in excellent yield and purity. For the linker 
MPXAL, the cleavage was achieved in 10 min (80 % yield) and 5 min for DMPXAL (90 
% yield) with 1% TFA/DCM. 
Safety catch amide linker (SCAL)36 is available in the SO form and the S form. 
In the SO form this linker is stable to 100 % TFA, reagent K, 50 % piperidine, HF and 
Pd(0) treatment. In the S form is stable to 50 % piperidine but it cleaves with mixture K 
and 50 % TFA. Synthesis of peptides can be accomplished by Fmoc, Alloc and /or Boc 
strategy. The SCAL linker was used successfully in the synthesis of a segment related to 
human calcitonin(figure 1.23). H-Phe-Gln-Thr-Ala-Ile-Gly-Val-Gly-Ala-Pro-NH2 was 
obtained in 95 % purity (HPLC) after cleavage with 1M-Me3SiBr/thioanisole/TFA, for 2h 
at 0°C.  This linker was found to have many advantages for solid-phase chemical 
ligation. vMIP I, a chemokine and 71 amino acid protein, that contains all 20 natural 
amino acids was prepared in a three-segment synthesis. Recovered yields were about 10-
15 % for three and four segment ligations. 
Benzyl alcohol linkers developed by Sheppard and Williams38  are illustrated in 
figure 1.26: a) They are is stable to acid and its peptides esters are cleaved by acid or 
nucleophilic reagents. One of the most common reagents for this is ammonia in the 
preparation of peptide amides. (b) Benzyl ester-type: acid labile on resin-bound esters are 
compatible with Boc-benzyl chemistry. The cleavage requires a strong liquid hydrogen 
fluoride solution. (c) The p-alkoxy derivative has better lability over b and has been used 
in the Fmoc-t-butyl polyamide method. The peptide ester bond is cleaved by TFA. (d) 
These two safety catch linkers37 figures 1.24 and 1.25 are derived from 4-
methylsulfinylbenzyl protecting group(Msob) are easily cleaved by mild acid. They are 

































HXVL n=4 MPXAL R=H
DMPXAL R=OCH3  
Resin  = polystyrene DMPXAL 




Type of Peptide = amide peptide 
 





acid aminomethyl resin(XAAL), 9-hydroxy-xanthen-3-yloyacetic acid 
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activated by a reductive acidolysis in the final deprotection step. The best protecting 
groups for the first linker Boc-DSA--Ala-NH-linker (figure 1.24) are Msob or tert-butyl 
on Asp residues, this is to prevent the formation of succinimide from Asp-containing 
peptides which can be a side reaction dependent on the amino acid sequence. The peptide 
(figure 1.24), Buccalin was synthesized in 40 % overall yield after cleavage with 
TFA/DCM. 
Boc-Leu-O-DSB-ß-Ala-NH-linker was used to prepare a 17-amino acid residue 
peptide. γ-Endorphin was synthesized with amino acid derivatives bearing safety catch 
protecting groups SPPS in which in situ neutralization and BOP activation were 
employed. The cleavage yield (figure 1.25) was 82 % as determined by amino acid 
analysis of the hydrolyzate of the resulting resin. The crude peptide was purified to γ-
endorphin in 62 % overall yield. 
The 2,4-dialkoxy benzyl alcohol derivative polymer bound esters can be cleaved 
by 1 % TFA in dichloromethane, under controlled conditions t-butyl groups remain in the 
















Peptide = H-Phe-Gln-Thr-Ala-Ile-Gly-Val-Gly-Ala-Pro-NH2 
Purity =95 % by HPLC 
Yield= essentially quantitative cleavage 
Resin = Benzyl amine resin 
Coupling Method = Fmoc/Boc 
Figure 1.23 Peptide cleavage from SCAL linker. 


















Resin  =  alanylaminomethylated polystyrene 
Peptide= Buccalin (H-Gly-Met-Asp-Ser-Leu-Ala-Phe-Ser-Gly-Gly-Leu-NH2) 
Yield = 40 % (77 % Cleavage Yield) 
Coupling Method=  Boc/DIPCDI/DMAP 
Type of Peptide =   Peptide amides 





















Resin  =  alanylaminomethylated polystyrene 
Peptide= γ-Endorphin (H-Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-
Val-Thr-Leu-OH) 
Yield = 62 % (80 % Cleavage Yield) 
Coupling Method=  Boc/BOP/iPr2EtN 
Type of Peptide =   Peptide carboxylic acids 











a) b) c) d)  
Figure 1.26 Benzyl alcohol linkers. 
 
This acetophenone-based linker40 in figure 1.27 linker is compatible with Fmoc 
chemistry. Peptides can be cleaved with 20 % TFA/DCM. The peptide Fmoc-Glu-His-
Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-OH was prepared with this linker (64 % yield). 
 











Resin = SynPhaseTM PS grafted crowns 
Peptide = Fmoc-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-OH 
Yield = 64 % 
Purity = 75 % 
Coupling Method=  Fmoc/DIC/HOBt 
Type of Peptide = Peptide carboxylic acids 
 
Figure 1.27 Peptide cleavage from an acetophenone-based linker. 
 
The p-alkoxybenzyl linker2 was utilized (figure 1.28) to synthesize large numbers 
of different peptide sequences. Instead of using polystyrene resins or its derivatives 
cellulose paper discs are used as solid supports for SPPS. Loading of the discs is about 
2.5 umol/disc. The peptide chains are linked to the cellulose via a p-alkoxybenzyl ester 
anchor whis is cleaved by mild treatment with trifloroacetic acid/DCM. This linker is 
compatible with Fmoc protected amino acids. Cellulose paper is very resistant towards 
organic solvents but it disintegrates with strong acids. The acid sensitivity prohibits the 
use t-Boc peptide synthesis but it still allows mild-acid peptide cleavage. The p-
alkoxybenzyl alcohol derivative releases ester bound peptides quantitatively by treatment 
by treatment with 50 % or less trifluoroacetic in DCM. The cleavage cocktail used was 
TFA/anisole/dichloromethane (55/5/40 by volume for 2.5 h at RT).  





Figure 1.28 p-Alkoxybenzyl linker. 
 
 
 In this example41 the hydroxymethyl phenyl valeric acid(HMPV) linker is used 
to prepare potential peptide turn mimetics. The peptide in figure 1.29 was cleaved from 
the resin using 1 % TFA/DCM (68 % Yield). This linker is compatible with  Fmoc 
















Peptide= Peptide Mimetic 
Yield = 68 % 
Coupling Method= Fmoc/HBTU/HOAt/collidine 
Type of Peptide = Peptide carboxylic acid 
Figure 1.29 Cleavage of peptide mimetic using HMPV linker. 
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p-Carboxybenzaldehyde42 resin is useful to make peptides such as  ocreotide 
















Resin  =  Rink amide 
Peptide= Ocreotide 
Yield = 74 %(after HPLC 
Type of Peptide =  amide 
Coupling Method= Fmoc/HOBt/HBTU/DIEA in NMP 
 
 




Arginyl derived linker43 (figure 1.31)is useful for peptidyl and peptidomimetic  
argininal derivatives. In this example (figure 1.31) the peptide is cleaved from the resin 
with TFA, CH2Cl2, H20: 6,3,1. 
The oxazolidine linker44 (figure 1.32) allows straight forward and direct attachment of 
aldehyde functionality to the solid phase. This oxazolidine linker is compatible with 
Fmoc peptide synthesis, including TFA treatment, but is cleaved by mild aqueous acid at 
60 C. 
















m - (Ph3P)4Pd(cat), THF, DMSO, 0.5 N HCl, morpholine: 2,2,1,5;
n  -  TFA, CH2Cl2, H2O: 6,3,1  
Resin  = AM-resin 
Yield = 55 %  
Purity = 97 % purity (HPLC) 
Coupling Method= PyBOP/DIEA/DMF 
Type of Peptide = Peptide Aldehydes 













Resin  =  Synphase crown 
Peptide= Ac-Tyr-Ala-Phe-Val-H 
Purity = High 
Type of Peptide = Peptide Aldehydes 
Coupling = DIC/HOBt 
Figure 1.32 Peptide cleavage from oxazolidine linker. 
 
 
p-Aminoanilide linker45 is useful for preparing p-nitroanilide (PNA) 
chromogenic substrates to study the kinetics and specificity of proteolytic enzymes. It is 
compatible with both Boc and Fmoc chemistries. This handle was prepared using 
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hydroxymethyl resin from highly substituted chloromethyl resin. This method works for 
most amino acids except those containing easily oxidized amino acids like methionine, 















Resin  = Urethane linked p-aminoanilide(UPAA) 
Peptide= Succinyl-Ala-Ala-Pro-Arg-PNA 
Type of Peptide = paranitroamines, para-nitroanilides (after oxidation with NaBiO3) 
Coupling Method= Boc 
Figure 1.33 Peptide cleavage from p-aminoanilide linker. 
The silyl phenyl linker46 (figure 1.34) for reverse-direction SSPS doesn’t need a 
spacer group like many other silyl linkers. After the synthesis, the resin can be recycled. 
The activation of the amino acids was carried using i-butyl chloroformate/N-
methylmorpholine. Other standard conditions such as DCC/DMAP: HBTU/HOBT, 
DIPEA; HOBT, DIPCDI were less effective. Cleavage of the free amine leaves behind 
only CO2 as by-product. 
The linker 4-[1-[N-(9-fluorenylmethyloxycarbonyl)-amino]-2-(trimethylsilyl) -
ethyl]-pheno-xyacetic acid linker “SAL” 47 takes advantage of organosilicon chemistry. 
This linker was designed to undergo deblocking by a β- elimination mechanism under 
acidic conditions. This linker is useful for peptides with C-terminal tryptophan, which are 
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obtained, only in poor yields using conventional linkers. This linker is also stable to 













f : HF, CH3CN; g : (Boc)2O, Et3N (Peptide)  
Resin  =  polystyrene 
Peptide= above is fine Pro-Phe-Gly-Phe-Phe(O-All) 
Yield = 54 % 
Coupling Method=  i-butyl chloroformate/N-methylmorpholine 
Type of Peptide =   Allyl or Methyl Ester 
















Resin  =  (aminomethyl)polystyrene resin 
Peptide= Bz-Ala-Gly 
Yield = 95 % yield 
Coupling Method=  Fmoc/DIEA/HOBt 
Type of Peptide = Peptide Amides 
Figure 1.35 Peptide cleavage using SAL linker. 
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p-Alkoxybenzyl alcohol linker48 is suitable for the preparation of protected 
peptide fragments. In this example a protected peptide (figure 1.36) was released from 






Bzl NO2 Bzl Tos
Z-Asp-Arg-Val-Tyr-Val-His-Pro-Phe
Bzl NO2 Bzl Tos
XVII




Resin  =  Merrifield 
Peptide= Z-Asp(Bzl)-Arg(NO2)-Val-Tyr(Bzl)-Val-His(Tos)-Pro-Phe 
Yield = 15 % (overall yield after side chain amino acid deprotection) 
Coupling Method=  Bpoc/DCC/pyridine      
Type of Peptide = Peptide carboxylic acid 
Figure 1.36 Peptide cleavage from p-Alkoxybenzyl alcohol linker. 
 
The linker (p- alkoxybenzyl-oxycarbonylhydrazide linker) 48. 
(figure 1.37) is useful in the preparation of peptide hydrazides. A model peptide Phe-Val-
Ala-Leu-HNNH2 was synthesized and cleaved with 50 % TFA (42 % yield). 
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OCH2Phe-Val-Ala-Leu-HNNH-COOCH2
50 % TFA, 30 min
Phe-Val-Ala-Leu-HNNH2  
Resin  =  Merrifield 
Peptide= Phe-Val-Ala-Leu-HNNH2 
Yield = 42 % (overall yield) 
Coupling Method=  Bpoc/DCC/pyridine 
Type of Peptide =   Peptide hydrazides 
Figure 1.37 Peptide cleavage from p- alkoxybenzyl-oxycarbonylhydrazide linker 
 
Alkyloxycarbonylhydrazide linker49 is similar to the one previously reported by 
Wang but it has two methyl groups in the  position of the carboxylic acid. The addition 
of these carbonyl groups increases the yield of the peptide synthesis two fold from the 









Resin  =  styrene- 2% divinylbenzene (200- 400 mesh) 
Peptide= Phe-Val-Ala-Leu-HNNH2 
Yield = 76 %  
Coupling Method=  Bpoc/DCC/pyridine 
Type of Peptide = Peptide hydrazides 
Figure11.38 Peptide cleavage from alkyloxycarbonylhydrazide linker. 
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The imidazole trityl resin50 in figure 1.39 was used to prepare head to tail 
histidine-containing cyclopeptides by a three- dimensional orthogonal solid phase 
strategy (Fmoc/tBu/allyl).  The imidazole ring was anchored to the resin of a peptide. 













i) Peptide chain elongation
           (5 cycles)




Resin  =  Fmoc-His(Trt-Resin) 
Peptide= Cyclo(-His-Gly-)3 
Coupling Method=  Fmoc/tBu/allyl (HATU/DIPEA) 
Type of Peptide =   cyclopeptides 
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CHAPTER TWO 
DESIGN AND SYNTHESIS OF NOVEL FERROCENE LINKER 
 
2.1. Introduction 
Despite their usefulness for the chemical synthesis of peptides, strong acids which 
are often used as deprotecting reagents have led to side reactions and to loss of peptide 
products usually resulting from  modification of peptides by the carbocations generated 
during the cleavage reaction. That is why there is a  need for improvement of linkers.  
In solid phase synthesis, synthetic transformations are conducted with one of the 
reactant molecules attached to an insoluble material referred to as the solid support. It 
was originally developed for peptide synthesis and then oligonucleotide synthesis. 
Linkers are molecules that keep the intermediates in solid-phase synthesis bound to the 
support. Peptides can be cleaved from the resin easier if they are attached to the resin 
through a labile linker. Generally a linker is necessary to achieve a good yield in solid 
phase peptide synthesis. Linkers should enable the easy attachment of the starting 
material to the support, be stable under a broad variety of reaction conditions, and yet 
enable selective cleavage at the end of the synthesis, without damage to the product. 
There are different types of linkers that meet these conflicting requirements to some 
extents. Linkers can be prepared so they yield amides, carboxylic acids or sulfonamides 
among others. The aim of this study was to design new solid support linkers for peptides 
that are commonly found in medicinally important agents. 
A series of linkers have been developed which yield amides upon cleavage  
[figure 2.1 a)]. The most common strategies used to date for the release of amides from 
insoluble supports are: (a) cleavage of a benzylic C-N bond of resin-bound N-alkyl-N-
benzyl amides, (b) nucleophilic cleavage of resin bound acylating agents with amines and 
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(c) acylation/debenzylation of resin-bound N,N-dibenzylamines 51. Incorporation for the 































Little is known about ferrocene adducts being incorporated into solid-phase 
peptide synthesis. In an attempt to increase the efficiency in our solid phase peptide 
synthesis a new type of linker was designed. This linker consists of a ferrocenyl moiety 
instead of the benzyl group used in most of the acid labile linkers developed up to date. 
Based on the ferrocenium carbocation stability,53,54  it was considered important to test 
the hypothesis that a peptide cleavage would occur under very mild acidic conditions in 
                                                                                                                              37
which a ferrocenium carbocation and a terminal amide group form at the point of 












Figure 2.2 Ferrocenyl carbocation formation by acid cleavage. 
2.2. Design of the Ferrocene Linker 
Different synthetic routes were explored to obtain a molecule that contains a 
ferrocenyl amino bond and a carbon chain that will allow attachment of the linker to the 















Figure 2.3 a) Ferrocene linker attached to resin and site of cleavage on the same site; b) 
Ferrocene linker attached to the resin and cleavage site on different sites of the 
cyclopentadienyl ligands. 
 
In the first case a) both the ferrocenyl amino and carbon chain that attaches to the 
resin are on the same ferrocenyl carbon, and in b) the carbon chain that connects the 
linker to the resin is on different cyclopentadienyl ligands. 
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2.3 Results and Discussion  
  Figure 2.4 illustrates a retrosynthetic route toward the target molecule for the 
linker of the type a. This route involves Friedel Crafts acylation and reduction of the 


















Figure 2.4 Retrosyntetic analysis of the ferrocene linker. 
 
The first attempted forward synthetic route to the linker is outlined in figure 2.5. 























Figure 2.5 Attempted forward synthetic route. 
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Attempts to reduce the ketone formed the lactone instead. To prevent the lactone 
formation, the preparation of the tert-butyl ester was unsuccessfully. Failed attempts to 



















































 Figure 2.6 Failed initial attempts to generate the ferrocenyl amine. 
 
It is known 5-membered rings are usually formed easily due to entropy factors 
followed by 6- and 3-membered rings. To prevent the lactone (ring) formation, an 
increase in the carbon chain to 6 carbons was performed. Now the lactone formation 
would be less favorable because 7-membered ring closures are less favorable. To prepare 
the compound with 6 carbons between the linker and the resin the original synthesis was 
modified.  The ferrocene Friedel Crafts acylation was easily done with methyl adipoyl 
chloride(figure 2.7).   









2.1 2.5  
 
Figure 2.7 Ferrocene Friedel-Crafts acylation with methyl adipoyl chloride. 
 
 
But it was found that the methyl ester of this compound has low solubility in 
organic solvents and the deprotected acid has low solubility in aqueous and polar 
solvents, which made the reduction of the ketone to the amine difficult. At this point the 
synthesis of linker type a) was abandoned and it was decided to make a linker of the type 
b) (figure 2.3). 
Two linkers were successfully synthesized each has the ferrocenyl amine bond 
and the carbon chain that attaches to the resin on different cyclopentadienyl rings of the 
ferrocene. The synthesis of the first linker is summarized in figure 2.8.  The synthetic 
steps involved Friedel-Crafts acylation with chloromethyl methyl ether and then coupling 
to the solid support. The solid support in this case is Clear Resin in which most of the 
core CLEAR structure is composed of ethylene glycol (-CH2-CH2-O-)n units.  Then 
reductive amination on solid support using sodium cyanoborohydride and heptenyl amine 
was done. 
To make the ferrocene 1-carboxylic acid-1`carboxaldehyde, there was no need to 
protect the carboxylic acid during the Friedel-Crafts acylation if the equivalents of 
aluminum chloride were doubled (figure 2.9). 
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After the synthesis and characterization of the linker it was tested in a peptide 




















Figure 2.10 Ferrocene linker amino acid coupling. 
The cleavage yield for peptides or just one amino acid was <5 %.  When this 
linker was designed it was beleived that ferrocene was going to provide enough stability 
to the carbocation formed regardless of the functional groups attached to the ferrocene. 
The amide that holds the ferrocene to the solid support is an electron-withdrawing group. 
Since this group can lower the carbocation stability it was a good idea to replace this 
group with an electro-donating group.  
The synthesis of the new linker with an electron-donating group is summarized in 
figure 2.11.  The synthesis of the linker was carried out in only 3 steps. The synthesis 
started with the Merrifield resin functionalized with triphenyl phosphine 2.13 and 
ferrocene dicarboxaldehyde 2.15. The reaction gave the desired product, confirmed by 
solid state NMR and later by Fmoc cleavage of the amine attached to the linker. The 
reductive amination with allyl amine and sodium cyanoborohydride gave the linker 2.16. 
A model  three-residue peptide(Ala-Gly-Phe-Fmoc) was synthesized and it was 
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characterized by FAB. A big increase in the cleavage product (40 %) was observed 





















2.15 2.16  
 










2.1 2.2  
To a solution of ferrocene (1.86 g, 0.01 mol) and succinic anhydride (1.0 g, 0.01 
mol) in 1,2-dichloroethane (50 mL), anhydrous aluminum chloride (2.67 g, 0.02 mol) 
was added and refluxed for 12 h. After cooling the solution, water (50 mL) and 
concentrated HCl (50 mL) were added to the solution, and the organic layer was 
separated. The organic layer was washed with concentrated sodium carbonate solution 
with a final pH of 10. The aqueous layer was separated and 6N HCl was added to the 
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solution with a final pH of 3. The aqueous layer was extracted with ether (50 mL × 3). 
The organic layers were combined and washed with water (50 mL x 2), followed by 
drying with Na2SO4. The solvent was removed in vacuo. Yield 1.87 g (65 %). 1H-NMR 
(250 MHz; CDCl3) 11.352 (s, 1H), 4.885 (s, 2H), 4.415 (s, 4H), 4.215 (s, 4H), 3.625 (t, 
2H), 2.598 (t, 2H) ppm. 13C-NMR (250 MHz; CDCl3) 202.012, 177.496, 79.781, 77.982, 
77.673, 76.972, 66.689, 32.661, 29.766 ppm. 
 











2.2 2.3  
 
To a solution of 4-ferrocenyl-4-oxobutanoic acid (0.95 g, 3.3 mmol) in CHCl3, 
20% aqueous solution of Cs2CO3 (~ 25 mL) was added to a pH of 10. The mixture was 
evaporated in vacuo. The residue was stirred with allyl bromide (0.48 g, 4.0 mmol) in 
CHCl3 for 6 h. The mixture was washed with water (3 x 40 mL), and the organic layer 
was dried over Na2SO4. The solvent was removed in vacuo. The ferrocene derivative was 
recrystallized by dissolving the crude material in a hot ethanol solution, followed by slow 
cooling to room temperature. Yield 0.75 g (70 %). 1H-NMR (250 MHz; CDCl3) 5.995 
(m, 1H), 5.325 (q, 2H), 4.853 (s, 2H), 4.525 (s, 4H), 4.215 (s, 5H), 3.090 (t, 2H), 2.661(t, 
2H) ppm. 13C-NMR (250 MHz; CDCl3) 28.242, 34.561, 65.742, 69.590, 72.639, 76.978, 
77.698, 78.774, 118.657, 132.607, 173.191, 202.473 ppm. MS, m/e (M+) 326. 
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2.1 2.17  
To a solution of 2-propenyl-4-ferrocenyl-4-oxobutanoate (0.53 g, 0.003 mol) in 
benzene (40 mL) p-toluenesulfonhydrazide (0.56 g, 0.003 mol) was added and refluxed 
for 12h. The product was present in the reaction as indicated by MALDI. However it was 
not isolated in a sufficient quantity to continue with the synthesis. MALDI (Matrix 
Assisted Laser Desorption Ionization) (M+H)+ 497.10. 
 









2.1 2.5  
 
To a solution of ferrocene (5.30 g, 0.0285 mol) and methyl adipoyl chloride (7.67 
g, 0.043 mol) in CH2Cl2 (50 mL), anhydrous AlCl3 (3.8 g, 0.02 mol) was added and 
refluxed for 12 h. After cooling the solution, ice-cold water (50 mL) was added to the 
solution, and then the organic layer was separated. The organic layer was washed with a 
5 % solution of NaHCO3. The solvent was removed in vacuo. The product was purified 
by flash chromatography starting with a hexane: ethyl acetate 4:1 mixture increasing the 
concentration of ethyl acetate gradually. Yield 1.87 g (80 %). MS, m/e 328, MALDI, 
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329.07. 1H-NMR 4.390-4.001 (m, 9H), 3.60 (s 3H), 2.741-1.242 (m, 8H) ppm. (250 
MHz; C6D6). 13C-NMR (250 MHZ; CDCl3) 206.132, 174.046, 76.083, 72.847, 70.381, 
69.920, 52.044, 39.420, 33.854, 25.096, 24.824 ppm. 
 
















2.5 2.18  
 
To a solution of 2-methyl 4-ferrocenyl-4-oxohexanoate (0.53 g, 0.003 mol) in 
benzene (40 mL) p-toluenesulfonhydrazide (0.56 g, 0.003 mol) was added and the 
mixture was allowed to reflux overnight. The product was present in the reaction as 
indicated by MALDI. However it was not isolated in a sufficient quantity to continue 
with the synthesis. MALDI (M+H)+ 497.10. 
 
 













To a solution of ferrocene carboxylic acid55 (1.01 g, 3.7 mmol) in CH2Cl2 (30 
mL) under argon was added pyridine (1 mL, 12.4 mmol). The suspension was cooled to 0 
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°C. Cyanuric fluoride was added (2.60 mL, 20 mmol), and the contents were stirred for 
1h to provide an orange solution. Crushed ice/water (30 mL) was added, the contents 
were filtered, and the organic layer was separated and washed with cold water. The 
organic layer was then dried with CaCl2, filtered, and concentrated in vacuo. The solid 
was dissolved in acetone, precipitated with cold water, filtered, and dried in vacuo. Yield 
0.89g (88 %), mp 166.5-167 °C.  1H-NMR (250MHz;CDCl3) 4.898 (s, 1H), 4.5873 (s, 
1H), 4.5800 (s, 1H), 4.3148 (s, 1H) ppm, as reported in the literature. 
 
 










2.19 2.12  
 
 
To a solution of (0.2 mmol) of  ferrocenyl-1,1-acid fluoride and (0.2 mmol) 4-
(dimethylamino)pyridine in dry CH2Cl2 was added (0.2 mmol) of methanol. The mixture 
was stirred at room temperature for 12 h and purified by recrystallization ether: hexane 
10:1 mixture. 1H-NMR (250 MHz; C6D6) 4.814 (s, 1H), 4.805 (s, 1H), 4.794 (s, 1H), 
4.406 (s, 1H), 4.397 (s, 1H), 4.386 (s, 1H), 4.206 (s, 1H), 3.8059 (s, 1H) ppm as reported 
in the literature.55 13C-NMR(250 MHz; C6D6) (data not found in literature) 172.606, 
73.020, 72.551, 71.613, 71.063, 66.422, 52.273, ppm. 
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2.12 2.13  
To an ice-cold mechanically-stirred CH2Cl2 solution (100 mL) of methyl 
ferrocenecarboxylate (11.5 g, 0.047 mol) and dichloromethyl methyl ether (5.4 g, 0.047 
mol), was added AlCl3 (12 g, 0.188 mol) in small portions using a solid addition funnel. 
The reaction was maintained at 0ºC for 0.5 h. Water (100 mL) was added in small 
portions to quench the reaction. The product was extracted with CH2Cl2. The organic 
phase was dried over NaSO4, and the crude product was chromatographed over silica 
with ethyl acetate: hexane, in a 1:2 mixture. Yield 10.35 g (87 %). The product was 
obtained as a red solid, mp 83-84°C, 1H-NMR (250 MHz; C6D6) 3.80 (s, 3H), 4.45 (t, 
2H), 4.58 (t, 2H), 4.80 (t, 2H), 4.88 (t, 2H) 9.95 (s, 1H) ppm. 13C-NMR(250 MHz; C6D6) 
(data not found in literature) 193.155, 172.183, 75.047, 74.717, 73.434, 72.699, 72.084, 
52.475 ppm 
 






To a solution of 6-cyano-hex-1-ene (15 g, 0.1374 mol) in tetrahydrofuran under 
argon at  0 C was added dropwise a 1.0 M solution of LiAlH4 in ethyl ether (137 ml, 
0.1374 mol). The mixture was refluxed overnight at 70  C  and then quenched at 0 C 
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with water (12 ml), 15 % NaOH (12 ml) and water (24 ml). The mixture was filtered and 
the organic layer was separated. A 1M solution of NaOH was added to the aqueous layer 
and extracted with dichloromethane until the extracts gave a negative ninhydrin test. The 
organic layers were combined and evaporated in vacuo. The oily product was distilled 
under vacuum (60 mm of mercury) and 1ml fractions were collected. Purity was 
confirmed by TLC with methanol: ethyl acetate: triethylamine (10:10:1) followed by 
nynhydrin test. The product was dried with NaOH pellets (1 pellet / ml of amine), which 
gave pure (by NMR) product 10g (65 % yield). 
 

















2.13 2.21  
 
 
 To a solution of glycine ethyl ester hydrochloride (2 mmol) and triethylamine (2 
mmol) in dry CHCl3 was added  (2.13) (2 mmol) and refluxed for 10h. The solvent was 
removed in vacuo. The imine was obtained as a yellow solid. The purity was checked by 
1H-NMR. The organic phase was dried and evaporated to afford ferrocenyl imine methyl 
amino acid in 90% yield. 1H-NMR (250 MHz; C6D6) 7.855 (s, 1H), 4.299-4.031 (m, 
11H), 3.646 (s, 3H), 1.431 (m, 3H), 1.097 (m, 2H) ppm. 13C-NMR confirms the presence 
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of the product. 13C-NMR (250 MHz; C6D6) 173.352, 172.588, 165.272, 73.752, 73.294, 
72.645, 71.568, 63.292, 61.779, 52.319, 15.261 ppm. 

















2.21 2.22  
 
 To a solution of the imine in dry CH3OH, 4 equiv. of solid NaBH4 were added in 
small portions at 0 °C. After the mixture was stirred for 30 min, 20 mL water was added 
and the organic phase extracted with CHCl3 (3 x 40 mL). The solvent was removed in 
vacuo to afford the pure ferrocene methyl amino acid. Yield (~ 95 %). 1H-NMR (250 
MHz; C6D6) 4.4-3.32 (m, 15H) 1.79-1.02 (m, 4H) ppm.  
 












2.6 2.7  
  To a solution of ferrocene carboxylic acid (10 g, 0.04 mol) and aluminum 
chloride (22 g, 0.16 mol) in dichloromethane (250 mL) dichloromethyl methyl ether (5.0 
g, 0.04 mol) was added and stirred at 0 for 0.5 hours. Water (150 mL) and 2N HCl (150 
mL) were added to the solution, and the organic layer was separated. The organic layer 
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was washed with concentrated sodium carbonate solution with a final pH of 10. The 
aqueous layer was separated and 6N HCl was added to the solution with a final pH of 3. 
The aqueous layer was extracted with dichloromethane (100 mL × 3). The organic layers 
were combined and washed with water (50 mL x 2), followed by drying with Na2SO4. 
The solvent was removed in vacuo. The compound was purified with hexane/ethyl 
acetate (3:1). Yield 3 g (20%). The compound was characterized by NMR (figure 2.14). 
 
 















2.8 2.9  
 
 
A glass peptide reaction vessel equipped with a fritted glass was siliconized with 
Surfasil (Pierce) prior to the reaction. Clear-NH resin (1.7 g 0.66 meq) (Peptides 
International) resin was swelled in the reaction vessel for 1hr with dichloromethane 
(NMR in figure 2.12). To a mixture of 20 ml of dichloromethane and Clear-NH resin 
ferrocene 1-carboxylic acid-1`carboxaldehyde (1.11 g, 5.30 mmol)  
diisopropylcarbodiimide (0.66 g, 5.30 mmol), HOBt (0.71 g, 5.30 mmol) and 20 ml of 
dimethylformamide were added. The mixture was stirred with a nitrogen flow for 20 hrs 
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followed by rinsing of the resin with DCM (30 ml x 3), DMF (30 ml x 3), DCM. (30 ml x 
3) and diethyl ether (30 ml). The compound was characterized by NMR (figure 2.13). 
 
 
Figure 2.12 Clear-NH resin magic angle spinning 1H-NMR(CDCl3, 400 MHz). 
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2.9 2.11  
 
A glass peptide reaction vessel equipped with a fritted glass was siliconized with Surfasil 
(Pierce) prior to the reaction. Clear ferrocene carboxaldehyde resin was swelled in the 
reaction vessel for 1hr with dichloromethane. To a mixture of 20 mL of dichloromethane 
and Clear ferrocene carboxaldehyde resin hept-6-enylamine  (0.75 g, 6.63 mmol) was 
added and stirred for 10 min. A solution of sodium cyanoborohydride(0.41g, 6.63 mmol) 
in 20 ml of dimethylformamide was added and stirred with a nitrogen flow overnight 
followed by rinsing of the resin with DCM (30 mL x 3), DMF (30 mL x 3), DCM. (30 
mL x 3) and diethyl ether (30 mL). 
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  The peptide was synthesized using the Fmoc protecting group, HOBt/TBTU 
coupling reagents and HATU/DIEA was used for the first coupling. Lysine side chains 
were protected with Cbz. The peptide was cleaved from the resin using a solution 
(prepared fresh) composed of 88 % (10 mL) TFA, 5 % (0.5 mL) phenol, 2 % (0.2 mL) 
triisopropylsiliane, and 5 % (0.5 mL) dd water. The TFA solution was purged with argon. 
This cleavage solution was added to the resin/peptide under argon with exclusion of light 
and occasional shaking. After 2 hours the peptide/TFA solution was filtered and diluted 
with 100 mL of cold 20 % acetic acid. This solution was extracted with cold diethyl ether 
(50 mL x 4). The peptide was lyophilized two days and purified by HPLC and 
characterized by mass spectrometry. The crude product was purified by preparative 
reverse-phase HPLC on a Waters 15 µm Deltapak C4 column using a water (0.05 % 
TFA) and acetonitrile (0.05 % TFA) gradient system and the absorption was monitored at 
222 nm. Peptide purity was verified on a Vydac 5 µm C18 column using the same 
conditions (5 % yield calculated from resin substitution level).  Matrix assisted laser 
desorption ionization (MALDI) mass spectrometry was used to verify peptide mass.  
Agni 2534 calculated observed 2552 mass   (M+H)+. 
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A solution of ferrocene dicarboxaldehyde 2.14  (0.06 g, 0.23 mmol) and benzyl-
triphenylmethylphosphonium chloride resin 2.13  (0.33 g, 0.23 mol) in dichloromethane 
(30 mL) was refluxed for 10 min. DBU(1,8-diazabicyclo[5.4.0]undec-7-ene)  (1mL) was 
added and reflux was continued for 30 min. The mixture then was rinsed in a filter with 
DCM(3 x 40 mL), DMF(2 x 30 mL) and DCM ( 3x 40 mL).  
 












To a solution of ferrocene carboxaldehyde polystyrene resin and allyl amine 
(0.13g, 2.3 mmol) in DCM (20 mL) a solution of sodium cyanoborohydride (0.22g, 0.34 
mmol) in DMF was added and stirred overnight. The mixture then was rinsed in a filter 
with DCM(3 x 40 mL), DMF(3 x 40 mL) and DCM (3x 40 mL). The product was 
characterized by solid-phase NMR and the aldehyde proton was identified at 9.5351ppm 
(s, 1H). 









2.16 2.25  
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Allyl-amino ferrocenyl polystyrene resin was swelled in 20 mL of DCM. Fmoc-
phenylalanine (1.54 g, 4 mmol) HATU (1.52 g, 4 mmol) and DIEA (1.55 g, 12 mmol) 
were dissolved in DMF and added to the resin and the mixture was stirred overnight.  
 
2.4.19 Cleavage of (1-allylcarbamoyl-2-phenyl-ethyl)-carbamic acid 9H-fluoren-9-  









5% TFA/DCM , Et3SiH








40% Yield by weight after column
20% Yield by weight after column
2.25
2.26  
The resin was swelled in DCM for an hour. In two separate cleavage studies 5 % 
and 1 %  TFA solutions in DCM with 5 % triethylsilane were added to the resin. The 
mixtures were shaken slowly for 4 hours. The product[(1-allylcarbamoyl-2-phenyl-
ethyl)-carbamic acid 9H-fluoren-9-ylmethyl ester] TLC showed small impurities. The 
resin amino acid mixture was filtered using glass wool and the product was dried in 
vacuo. The product was washed with water (2 x 20 ml). The product was purified using 
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CHAPTER THREE 
 
CONVERGENT PEPTIDE SYNTHESIS 
 
3.1 Introduction 
Peptides are endogenous, polycationic molecules that have broad microbiocidal 
activity against various bacteria and fungi. Water-membrane soluble proteins and 
peptides are used in the defense and offense systems of all organisms, including plants 
and humans. 56-60 Peptides serve as nonspecific defense system that complements the 
highly specific cell mediated immune system.  Many bacteria are now resistant to the 
conventional antibiotics like penicillin 61,62. This has motivated the investigation of new 
antimicrobial agents with different mechanisms of action.  
These peptides are mobilized shortly after microbial infection, and act rapidly to 
neutralize a broad range of microbes. This rapid response is important because activation 
of pathogen specific immune responses occur slowly relative to the potential kinetics of 
microbial proliferation. Many of these antibacterial peptides are helix-forming peptides, 
which are amphipathic (with polar and nonpolar groups on opposite faces of the helix) a 
structural feature believed to be important in their function as antimicrobial agents. Most 
of these peptides are linear with a potential to form amphipathic -helical or -sheet 
structures, whereas others are cyclic due to the presence of one or more disulfide bonds 
or thioethers 63-67. Despite many similar sructural features among antimicrobial 
peptides, their spectrum of activity differs significantly and they can be classified into 
several groups: (1) peptides such as cecropins, 68,69 isolated from the cecropia moth that 
are toxic to microorganisms but not to normal mammalian cells and which are active 
mainly on Gram-positive bacteria. Others are active on both Gram-positive and Gram-
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negative bacteria, e.g.,magainins 70 and dermaseptins, both isolated from the skin of 
frogs. (2) Peptides that are toxic to both microorganisms and mammalian cells, such as 
the bee venom melittin, and the Moses Sole fish venom pardaxin.71,72 
Antimicrobial peptides represent a good alternative to traditional antibiotics 
because most of them kill bacteria by physical disruption of cell membranes, which may 
prevent microorganisms from developing resistance against these agents. The discovery 
of thousands of antimicrobial peptides with variable lengths and sequences suggests a 
general mechanism for killing bacteria rather than a specific mechanism that requires 
preferred active structures.  Antimicrobial peptides are considered promising drug 
candidates because of their potential to overcome bacterial resistance73-76. They are 
ancient components of all species of life, and their expression pathways in all organisms, 
including insects and plants, are conserved.  Conventional antibiotics penetrate the cell 
wall and act on specific targets. In these circumstances, the bacterial morphology is 
preserved and the bacteria can develop resistance. In contrast, most antibacterial peptides 
disrupt and permeate the target cell membrane and inflict irreversible damage.  The exact 
mechanism of antimicrobial action is not known but there are two proposed mechanisms; 
the raft or carpet model77 and the barrel-stave or pore model78.  The raft model does not 
require any specific structure or sequence and starts with the binding of the peptide to the 
surface of the membrane79. The membrane is disrupted after a threshold peptide 
concentration has been reached.  The peptide first binds to the phospholipid headgroups.  
The peptide helix assembles on the membrane of a bacterium so that the positively 
charged molecules can interact with the negatively charged phospholipid groups of the 
membrane79. The peptide inserts partially into the membrane so that the hydrophobic 
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residues interact with the hydrophobic core of the membrane and finally destruction of 
the membrane occurs by disruption of the bilayer curvature. In the pore model, 
amphipathic -helices form bundles in the cell, in which their hydrophobic surfaces 
interact with the lipid core of the membrane79.  In this orientation, the hydrophilic 
surfaces of the helices form a water filled pore. Membrane binding of the peptide is 
favored by hydrophobic interactions. It seems that when there is an appropriate balance 
between hydrophobicity and a net positive charge, the peptides destroy the susceptible 
cell79.  
Amino acids are the basic components of peptides. There are twenty naturally 
occurring -amino acids and hundreds of non-natural amino acids that have the general 
structure shown below (figure 3.1). Amino acids are also present in proteins but the term 
“protein” is usually used for those polypeptides that occur in nature and have definite 
three-dimensional structures under physiological conditions.80 This dissertation focuses 






Figure 3.1 General -amino acid structure. 
The distinguishing feature in the amino acids is the structure of the R group 
located at the -carbon. Some unnatural amino acids are routinely included in many 
peptide sequences. Side chains that do not occur in biological systems distinguish 
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unnatural amino acids from their natural counterparts. The R groups affect the peptide 
secondary structure. 
3.2 Secondary Structure 
Peptides can adopt defined 3-D structures. The -helix and the 310-helix are two 
of the most common helices in antimicrobial peptides (figure 3.2). Helices can be 
characterized by the number of residues (amino acids) per turn and the hydrogen-bonding 
pattern. In the -helix, there are 3.6 residues per turn of the helix. In a 310-helix, there are 
3 residues per turn. A combination of hydrogen bonding and hydrophobic, electrostatic 
and steric interactions stabilize the helix. The -helix is by far the most common; the 310-
helix makes up less than 10% of all peptide structures. 
 




Figure 3.2 Cylindrical representations of helical secondary structures. Cylinder to the 
right shows the main hydrogen bonding in an -helix. 
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-sheets form as a result of either inter or intramolecular hydrogen bonds between 
peptide segments.  Hydrophobic interactions further stabilize the -sheet.  Secondary 
structures that are not included above are classified as random coil.  The random coil has 
no regular, repeating structure in significant stretches of the peptide chain. 81 The -sheet 
results from two or more -strands forming interchain hydrogen bonds. Two types of -



































































Figure 3.3 Parallel and antiparallel -sheet hydrogen bonding. 
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3.3 Solid-Phase Peptide Synthesis Methods  
One of the difficulties associated with solid-phase peptide chemistry is prevention 
of reaction on functionalized side chains of amino acids such as lysine, glutamic acid and 
cysteine.  In order to prevent these reactions from taking place, side-chain protecting 
groups must be used.  These groups must be stable to the coupling conditions, stable 
under conditions that cleave the active terminus for continued growth, but labile under 
conditions which cleave the product from the resin, allowing for isolation of the fully 
deprotected product.  Thus, the N-terminal and side-chain protecting groups must be 
orthogonal to each other in a solid-phase coupling scheme.  Several coupling schemes 
have been developed which match linker, N-terminal protection and side-chain protection 
in an orthogonal manner.  Some of the most commonly used include the Boc-benzyl 83 
84 strategy (figure 3.4) 85 and the Fmoc-Boc strategy 86,87 (figure 3.5).85 
One aspect of solid phase synthesis that has seen tremendous development is in 
the field of coupling reagents.  Traditionally, peptide coupling under solid phase 
conditions can be realized in two ways:  1) A reactive electrophilic derivative of the 
amino acid, such as an acid halide88 or an N-carboxyanhydride (NCA) 89 can be 
synthesized, isolated and then allowed to react with the nucleophilic portion of the resin-
bound residue.  These active species are easy to synthesize and relatively stable, allowing 
for facile characterization.  In addition, the simplicity of by-products released from such 
couplings, such as a carbon dioxide, chloride or fluoride ion, allow for simple purification 
after coupling has occurred.  Alternately, a coupling reagent may be added to the reaction 
mixture, to generate a reactive electrophilic derivative in situ. These coupling reagents 90 
include carbodiimides91,92 such as DCC, DEC, and DIPCDI, HOBt 93 and HOAt 94,95 
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and tertiary ammonium salts of triazole N-oxides, such as HBTU 96and HATU 95 (table 
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The advantage of these types of coupling is the relative ease of handling of 
unactivated species, which are introduced into the reaction along with the coupling 
reagent.  In addition, in situ activation allows for the preparation of highly activated 
species that are often not isolable. 
 
 
Table 3.1.  Common coupling reagents used in SPPS. 





































































3.4 Convergent Peptide Synthesis 
Efforts have been devoted to increasing coupling yields such as the improvement 
of protecting groups, solid supports, coupling reagents, linkers and automation of SPPS. 
As a result of these improvements, several impressive linear solid-phase syntheses of 
peptides have been reported using the SPPS linear approach (table 3.2).   
 
 




48 Insulin-fragments 97,98 
99 HIV- protease 99 
126 Cardiodilatin 100 
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Successful peptide assembly is still hampered by problems such as poor solvation 
of the growing peptide chain during solid phase synthesis as well as limited solubility of 
fully protected peptide fragments in the solution approach, often leading to incomplete 
coupling steps102. It was believed that these problems were mainly caused by 
interactions between the peptide and the resin support,103 but recent work,104  shows 
that these undesirable physicochemical problems originate from intermolecular 
aggregation of the protected peptide chains and/or the formation of secondary structures, 
most notably of -sheets. These hydrogen bonds reduce solvation of the peptide, which 
decreases the access to the incoming activated amino acid resulting in low coupling. 
Hydrogen bonding is partially reversible which results in a series of deleted sequences 
making the separation and purification of the peptide difficult.  
  To overcome these difficulties, different convergent strategies have been devised, 
especially for homogeneous large molecules. Some of these methods involve protected 
peptide segments, which is generally referred as convergent solid-phase peptide 
synthesis(CSPPS) and the second method, which involves unprotected peptide segments, 
which is referred as chemo-selective ligation. 
    3.4.1 Convergent Solid-Phase Peptide Synthesis(CSPPS) of Protected Peptide 
Segments 
 
The CSPPS method was developed for the preparation of difficult and complex 
peptides and small proteins. In the step-by-step peptide chain elongation, the resin-bound 
C-terminal amino acid is reacted sequentially with suitably protected and activated amino 
acids. In this procedure, the peptide is elongated towards the N-terminal direction (figure 
3.6). Elongation performed from the N- to the C-terminus can be problematic because the 
C-terminal amino acid needs to be activated, which leads to its racemization. In CSPPS 
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method, the possibility for racemization is minimized by reducing the number of 
individual activation steps. In this method, protected peptide fragments rather than the 
free peptide can be cleaved from the solid support after synthesis. The protected peptide 
fragments are then purified by chromatography before coupling on a solid support thus 











In CSPPS, all reactive functional groups except the ones required for coupling are 
protected. These protecting groups must be stable to the cleavage conditions necessary to 
prepare each fragment. 
Protected segment solubility is one of the problems of CSPPS. Selecting 
compatible protecting groups for the individual segment usually can increase segment 
solubility. Usually peptide segments no longer than 15 residues are used in CSPPS. 
Longer segments usually give incomplete couplings. Successful segment couplings can 
take days 105, 106. Sometimes amide backbone protection is required to increase 
solubility.  Amide backbone protection of every 4-6 residues can be sufficient in many 
cases. This amide backbone protection prevents hydrogen bonding thus eliminating 
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unpredictable changes in conformation like -sheet-like and amide backbone hydrogen 






















Figure 3.7 Amide backbone protection. 
The TFA-labile N-(2-hydroxy-4 -methoxybenzyl) (Hmb) protecting group and its 
reversibly acid-stable counterpart, N-(2-acetoxy-4 -methoxybenzyl) (AcHmb) (figure 
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3.8)   are widely used in amide backbone protection. Literature reports demonstrate that 
the use of this type of amide backbone protection eliminates problems in syntheses 













a) b)  
Figure 3.8 a) Structures of Hmb and, b) Ac-Hmb  protecting groups for backbone amides.  
3.4.2 Chemoselective ligation of unprotected peptide fragments 
 Chemoselective ligation is similar to convergent synthesis in that large peptide 
fragments are coupled to other peptide fragments but the difference between the two 
techniques is that that in chemoselective ligation, the synthesis occurs with unprotected 
peptide fragments. This type of synthesis is carried in aqueous solution and is based on 
the selective formation of particular covalent bonds in the presence of the unprotected 
peptide side-chain functionalities. This type of approach has some benefits: by coupling 
small to medium sized peptides, the purification can be greatly simplified; and by using 
unprotected peptides, the problems of poor fragment solubility normally are eliminated.  
Chemoselective ligation was by introduced by Liu and Tam and others 107 108. 
There are three general methods (table 3.3) for the preparation of large peptides 
using unprotected segments. The first method is based on the thiol chemistry method, 
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which includes thioalkylation, thiol addition, and thiol disulfide exchange. The second 
method is based on carbonyl chemistry and involes an addition-elimination reaction 




Table 3.3. Methods for ligating unprotected peptides. 







R1-SH + X-CH2-CO-R2       R1-S-CH2-CO-R2 
R1-SH + R’-S-S-R2                 R1-S-S-R2 
 


























X = O or N 
 
X = O or S 
 
R1 = peptide 
Reverse proteolysis 
 
R1-CO-OH + NH2NH-CO-R2                             
R1-CONHNH-R2 
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Thiol chemistry exploits the reaction of sulfhydryls in the alkylation with -
halocarbonyls, addition to conjugated olefins, and sulfur-sulfur exchange with disulfides. 
Thioalkylation is very popular in protein chemistry as a way to attach ligands and 
peptides 109 because of the easy access of thiol groups in proteins 110. The ease of 
adding haloacetyl(-halocarbonyl) groups to peptides during stepwise solid-phase 
synthesis makes this type of chemistry convenient. Alkyl thiols are usually used in the 
form of cysteine, which can be coupled to a peptide using Fmoc chemistry. The 








Figure 3.9 Trityl protected cysteine. 
 
 
The haloacetyl residue can be attached to the N-terminus or the side chain of lysine 
positioned anywhere in the sequence 111. The haloacetyl moiety is stable to HF cleavage 
conditions in the absence of thiol scavengers.  The reagent of choice is usually 
bromoacetyl because it is more reactive than the corresponding chloro analog, especially 
in aqueous media. The iodo analog is used rarely because of instability to cleavage 
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conditions in solid phase synthesis. Synthetic peptides with N-bromoacetyl and C-
terminal cysteine are usually oligmerized at pH 7-8, to prevent formation of disulfide 
bonds.  
3.5 Results and Discussion 
The peptide in this study(Cyh-7) is comprised of 57% of an ,-disubstituted 
amino acid.  The ,-disubstituted amino acid increases the stability of the helix112. 
This peptide was designed be to helical and it can form an amphipathic -helix (figure 
3.10) or an amphipathic 310-helix. The peptide synthesis of Cyh-7 was successful and the 
biological activity of this peptide was significant. At this point chemical ligation was 























a.                           b. 
 
Figure 3.10 Structure of Cyh-7 peptide and structures of 1-amino-1-cyclohexane-
carboxylic acid (a) and lysine amino acids (b). 
 




                  -Helical wheel                                                      310-helical wheel 
     
Figure 3.11 Helical wheel motifs showing -helical and 310-helical conformations of 




The coupling yield for each step in the synthesis of Cyh-7 was lower than 85 % 
and in most cases, just 70 %, so if a longer sequence was needed a more efficient route 
other than stepwise synthesis was necessary in order to synthesize the peptide. Thus 
several synthetic convergent routes were deviced to make this peptide.  
The first synthetic strategy was cross metathesis. To allow this, a new linker(16-
hydroxypalmitoleic acid) was synthesized in just one step from aleuritic acid. The double 
bond in the molecule, in theory, will cleave the peptide from the resin using a ruthenium 
catalyst. Figure 3.12 shows the strategy proposed. 




















Figure 3.12 Peptide cleavage using a ruthenium catalyst. 
 
 
Attempts to form an ester bond between the terminal alcohol of the linker and the 
first residue of the peptide failed. This is probably due to solubility problems. Other 
methods to make shorter linkers with a double bond in the center were in theory easy, but 
costly compared to our next strategy. In this strategy, the double bond is at the side chain 
of a commercially available amino acid and the cleavage of the peptide from the resin is 
performed with commercially available resins with acid labile linkers. Two residues at 
the C-Terminus  and N-terminus of the model peptide (KLAKKLA)2 were added.  The 
first residue, the side chain of aspartyl allyl ester, bears a double bond that, when reacted 
with the ruthenium catalyst and the terminal residue bearing a double(figure 3.13) bond 
yields a cyclic peptide. The ring closing metathesis was attempted in several ways, but 
the desired product it was not obtained.  


















































































































Figure 3.13. a) Peptide ligation using Grubbs-Hoveyda ruthenium catalyst and b) Peptide 
ligation using Grubbs ruthenium catalyst. 
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3.6 Experimental 
  3.6.1 Peptide Synthesis 
 
The solid phase peptide synthesis was carried out using Fmoc amino acid 





















Structure of Fmoc  
 


















Fmoc-1-Amino-1-cyclohexane-carboxyl fluoride  
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General peptide synthesis procedure steps: 
 
1. Deprotection (figure 3.15). 
The Fmoc protection of the support-based amino acid is removed with a solution 
containing a mild base (20 % Piperidine/DMF/2 % DBU) to liberate the amino group for 
coupling. The spacer Fmoc-6-aminohexanoic acid is used to reduce the steric interaction 
between the peptide chain and the resin. The peptide synthesis was carried out on the 





















Figure 3.15 Fmoc deprotection. 
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2. Activation and Coupling (figure 3.16). The carbonyl fluoride group of the next amino 
acid is coupled with the deprotected amino group of the previous amino acid by 
formation of an amide bond. Excess reagents and high concentration are used to drive 




































Figure 3.16 Fmoc deprotection and amino acid coupling. 
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3. The deprotection and coupling steps are repeated until the peptide is fully assembled. 
4. The spacer Fmoc-6-aminohexanoic acid is coupled to the terminal lysine and the 
amino group of the spacer is Fmoc deprotected and is acetylated using Ac2O and 
pyridine. 
5. Cleavage of peptide from resin. The resin/peptide was rinsed with DCM and dried for 
a minimum of 4 h under vacuum. The cleavage solution was prepared fresh. It is 
composed of 88 % (10 mL) TFA, 5 % (0.5 mL) phenol, 2 % (0.2 mL) triisopropylsiliane, 
and 5 % (0.5 mL) dd water. The TFA solution was purged with argon. This cleavage 
solution was added to the resin/peptide under argon with exclusion of light and 
occasional shaking. After 2 hours the peptide/TFA solution was filtered and diluted with 
100 mL of cold 20 % acetic acid. This solution was extracted with cold diethyl ether (50 
mL x 4). The peptide was freeze dried for two days and purified by HPLC and 
characterized by mass spectrometry. 
  3.6.2 Cyh-7 
Cyh-7 was synthesized by manually coupling aminohexanoic acid onto a PAL-
PEG-PS solid support.  The couplings were done by reacting 8 equivalents of the Fmoc-
acid fluoride, 3 equivalents of DIEA and the resin in methylene chloride.  The reagents 
were allowed to react until an acceptable yield was determined by quantitative Fmoc 
tests. In some cases, the resin was rinsed with 3 x 20 mL portions of methylene chloride 
and treated with fresh reactants until >70 % coupling yields were obtained. A solution of 
20% piperidine/2 % 1,8-diazobicyclo [4.5.0]undec-7-ene (DBU) in DMF was used for 
Fmoc removal. The spacer, Fmoc-6-aminohexanoic acid, is coupled to the terminal lysine 
and the amino group of the spacer is Fmoc deprotected and is acetylated using Ac2O and 
pyridine. The resin/peptide was rinsed with DCM and dried for a minimum of 4 h under 
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vacuum. The peptide was cleaved from the resin using a solution (prepared fresh) 
composed of 88 % (10 mL) TFA, 5 % (0.5 mL) phenol, 2 % (0.2 mL) triisopropylsiliane, 
and 5 % (0.5 mL) dd water. 113 The TFA solution was purged with argon. This cleavage 
solution was added to the resin/peptide under argon with exclusion of light and 
occasional shaking. After 2 hours the peptide/TFA solution was filtered and diluted with 
100 mL of cold 20 % acetic acid. 113 This solution was extracted with cold diethyl ether 
(50 mL x 4). The peptide was lyophilized two days and purified by HPLC and 
characterized by mass spectrometry. The crude product was purified by preparative 
reverse-phase HPLC on a Waters 15 µm Deltapak C4 column using a water (0.05 % 
TFA) and acetonitrile (0.05 % TFA) gradient system.  The gradient was run from 15 % to 
45 % organic and the absorption was monitored at 222 nm.  Peptide purity was verified 
on a Vydac 5 µm C18 column using the same conditions.  Matrix assisted laser desorption 
ionization (MALDI) mass spectrometry was used to verify peptide mass.  Cyh-7 1192 
(M+H)+. 
  3.6.3 Cyh-7 MIC Assays 
E. coli American type culture collection (ATCC) 25922 and S. aureus ATCC 25922 were 
used as representative Gram-negative and Gram-positive bacteria in the MIC (minimum 
inhibitory concentration) assays.  The bacterial cultures were grown in nutrient broth to 
midlog phase and standardized using McFarland standard before dilution.  A 512 µg/mL 
peptide stock solution was prepared and 1:2 serial dilutions were prepared and added to 
the culture media to give final peptide concentrations of 256 µg/mL and less. 
Fifty microliters of cells (5 X 104) and 50 µL of the peptide solution were added to a 
sterile well and the MIC was determined by the lowest concentration that inhibited cell 
growth.  The inhibition of cell growth was indicated by the absence of turbidity, after 
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four hours.  Turbidity in the wells was visualized manually.  The MIC values are reported 
as the median value for at least three experiments. 
 
 
Table 3.4 Minimum inhibitory concentration of Cyh-7. 
 
Concentration 
g/mL. 256 128 64 32 16 8 4 2 
Inhibition Against 
E. coli. High High High High High Moderate Low Low 
Inhibition Against 

























Triethyl orthoformate (8.5 ml, 50.1 mmol), benzoic acid 0.25 g and aleuritic acid 
(5 g, 16.45 mmol were heated gently (~110 C) for 1 hr until the ethanol evaporated. The 
temperature was then slowly raised to 170 C for 4 hours. To this mixture, a 1 N solution 
of NaOH was added at room temperature and stirred overnight. HCl 2N was added until a 
pH of 10. The mixture was extracted with dichloromethane (3x 100 ml). The organic 
layers were combined, dried with sodium sulfate and dried in vacuo. The product was 
very pure by TLC but it can be purified using column chromatography (8 % methanol in 
chloroform). 
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  3.6.5 Peptide Synthesis Agni[ Glu(O-All)(KLAKKLA)2heptenoic Acid] 
The peptide was synthesized using the Fmoc protecting group, HOBt/TBTU coupling. 
Lysine side chains were protected with Cbz. The peptide was cleaved from the resin 
using a solution (prepared fresh) composed of 76 % (18 mL) TFA, 17 %(4 mL) 
dichloromethane 17 % (0.5 mL) phenol, 2 % (0.5 mL) triisopropylsiliane, and 2 % (0.5 
mL) dd water. The TFA solution was purged with argon. This cleavage solution was 
added to the resin/peptide under argon with occasional shaking. After 3 hours the 
peptide/TFA solution was filtered and diluted with 100 mL of cold 20 % acetic acid. The 
mixture was lyophilized two days.  
The peptide was dissolved in dichloromethane and it was washed with water. The 
organic layer was concentrated in vacuo. TLC 1:9 methanol/chloroform showed a major 
spot with minor impurities. Matrix assisted laser desorption ionization (MALDI) mass 
spectrometry was used to verify peptide mass.  2533   (M+H)+.     
  3.7 Ring Closing Methatesis Peptide Ligation 
 
The ruthenium catalyst was purchased from Senn chemicals [cas#194659-03-5]. 
Fmoc glutamic acid allyl ester was purchased from Neosystem. Heptenoic acid was 
synthesized as in the ferrocene linker I.  
The peptide Agni was synthesized using Fmoc amino acids. To a segment of the 
peptide Agni earlier reported by this group were added two residues.   
The C-terminus residue glutamic acid with the side chain as an allyl ester, which 
can undergo metathesis with other residues and heptenoic acid was used to undergo 
metathesis at the N-terminus residue. 
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  3.7.1 Attempted Peptide Ligation.  
To a solution of 0.0339mg (0.0073mmol) of the peptide in dichloromethane was 
added in 5 % by mol portions of the Grubbs-Hoveyda catalyst   until the total amount was 
40 % by mol. The reaction was monitored by TLC. MALDI was used to verify the 
appearance of peptide oligomers, but only masses below 1100 were observed. 
  3.7.2 Attempted Peptide Ligation  
 To a solution  of 0.2500 mg (.0050 mmol) of  the peptide in dichloromethane was 
added in 5 % by mol portions of the new Grubbs catalyst until the total amount was 40 % 
by mol. The reaction was monitored by TLC. MALDI was used to verify the appearance 


















SUMMARY AND FUTURE STUDIES 
4.1 Discussion 
In Chapter 2 of this dissertation, a novel ferrocene linker was prepared. The 
effects of the electron-withdrawing groups on the cleavage rates of molecules from 
the ferrocenyl-amine position were demonstrated. The ferrocenyl cation was 
stabilized with electron-donating groups to increase the cleavage rates. It was found 
that by having a vinylic bond instead of a carboxyl amide group directly attached to 
the cyclopentadienyl ring increases the acid lability of the linker. This suggests that 
other groups may be attached to the ferrocene in order to make linkers with different 
degrees of acid lability. These changes can be beneficial when different protection 
schemes are needed. In Chapter 3, ways to make antimicrobial helical peptides 
incorporating natural and unnatural amino acids were explored. A synthetic 
antimicrobial peptide Cyh-7 was synthesized and tested for biological activity, which 
proved to be significant. Attempts to make a longer homogeneous sequences using 
cross metathesis failed. Possible causes for this could be undesired conformations of 
the peptide in solution, which makes them inaccessible to react with the catalyst.  A 
study of the peptide conformation in suitable solvents for the catalysis may provide 
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